Deutsche Bank’s Gregg Gilbert is concerned about the unpredictability of VRX’s legal hurdles that lie ahead.
Mizuho’s Irina Rivkind Koffler says if TEVA can stabilize its business, it could evade a downgrade to high yield.
Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) served its third quarter earnings on Tuesday, but to Canaccord analyst …
J.P. Morgan’s Cory Kasimov is lowering expectations that were never high for ACOR Parkinson’s asset toz.
H.C. Wainwright’s Ed Arce spotlights significant prospective value creation for AUPH’s lead asset.
Cantor’s Louise Chen met with Teva’s team yesterday and still sees reason to be sidelined until generics pricing gets better.
Cowen places more importance on ORR strength than reduction in OS for IMMU’s prospects for a green light.
BMO stays on the sidelines as VRX still faces headwinds, but praises key “headway” in growth.
Unfavorable Teva risk/reward and steep valuation keeps Oppenheimer on the sidelines.
Two healthcare companies with recently approved and much-hyped products- but which one makes a compelling …